Carregant...
A randomized phase II study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer
BACKGROUND: Use of radiopharmaceutical may improve the survival time of patients with castrate-resistant prostate cancer and bone metastases. Whether androgen-deprivation therapy (ADT) combined with bone-targeted therapy provides clinical benefit for patients with advanced castrate-sensitive prostat...
Guardat en:
| Publicat a: | Cancer |
|---|---|
| Autors principals: | , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4270821/ https://ncbi.nlm.nih.gov/pubmed/25155428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28971 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|